Research and laboratory use only. Not for human consumption.
BPC-157
A synthetic 15-amino-acid research peptide associated with a gastric protein fragment and investigated primarily through preclinical research involving cytoprotection, tissue repair, gastrointestinal biology and musculoskeletal injury.
What is BPC-157?
BPC-157 is a 15-amino-acid peptide, or pentadecapeptide, whose sequence is GEPPPGKPADDAGLV. It is generally discussed in the scientific literature in connection with a gastric protein fragment and the broader “Body Protection Compound” research programme.
The compound attracted scientific interest because experimental research reported cytoprotective and tissue-repair-associated effects across a variety of laboratory and animal models.
Research subsequently expanded beyond gastric biology into models involving skeletal muscle, tendons, ligaments, bone, blood vessels and other tissues.
However, the large majority of the evidence remains preclinical. Modern systematic reviews continue to emphasise the substantial gap between experimental findings and reliable evidence in humans.
Why is it called BPC-157?
BPC stands for Body Protection Compound. The terminology originated from research into protective and cytoprotective activity associated with gastric material.
BPC-157 refers to the specific 15-residue peptide sequence investigated within this research area.
Scientific descriptions of the peptide's precise natural origin have not always been consistent. Modern pharmaceutical literature commonly describes BPC-157 as a synthetic pentadecapeptide derived from a gastric protein fragment. This is the terminology ASA Research uses throughout this information centre.
Amino-acid sequence
BPC-157 contains fifteen amino-acid residues arranged in a specific linear sequence. This primary structure defines the peptide's molecular identity.
Why are researchers interested in BPC-157?
BPC-157 has generated research interest because preclinical studies have reported biological activity across several tissue systems. These findings remain predominantly laboratory and animal observations.
Gastrointestinal Biology
The compound's research history is closely associated with gastric cytoprotection, mucosal integrity and experimental gastrointestinal injury.
Musculoskeletal Repair
Experimental models have investigated muscle, tendon, ligament and bone injury, creating substantial interest within sports-medicine research.
Vascular Biology
Preclinical work has examined angiogenic, endothelial and nitric-oxide-associated signalling pathways.
Cellular Repair
Experimental research includes fibroblast activity, cellular migration, collagen-related processes and tissue remodelling.
How might BPC-157 produce biological effects?
No single mechanism completely explains the experimental observations associated with BPC-157. Several interacting pathways have instead been proposed through preclinical research.
Angiogenic Signalling
Experimental studies have investigated pathways associated with blood-vessel formation and endothelial responses.
Nitric Oxide System
Interaction with nitric-oxide-associated signalling is repeatedly discussed in BPC-157 preclinical research.
Fibroblast Activity
Cell migration, fibroblast activity and collagen-related processes have been investigated in experimental tissue-repair models.
Cell Signalling
Growth-factor-related and intracellular signalling pathways, including ERK-associated mechanisms, have appeared in mechanistic studies.
What might BPC-157 eventually be investigated for?
Preclinical findings have generated hypotheses about possible future therapeutic applications. The areas below represent research directions — they are not established human uses or treatment recommendations.
Muscle Injury & Recovery
Animal models have investigated BPC-157 in skeletal-muscle injury and repair. This has helped drive interest in whether musculoskeletal findings might eventually translate into controlled human research.
Tendon & Ligament Injury
Tendon and ligament models represent one of the better-known areas of BPC-157 preclinical research. Reliable controlled human evidence demonstrating therapeutic benefit is currently lacking.
Gastrointestinal Research
BPC-157's scientific origins and extensive gastrointestinal animal literature have generated interest in mucosal protection and gastrointestinal injury as possible areas for further investigation.
Tissue-Repair Applications
Research involving vascular responses, fibroblasts, collagen organisation and cellular migration raises broader questions about tissue repair. Translation of these findings to human medicine remains uncertain.
Laboratory and animal findings cannot establish that BPC-157 is safe or effective for treating disease or injury in humans. Controlled clinical research is required before such conclusions can be made.
How strong is the evidence?
A useful way to understand BPC-157 is to separate the relatively large preclinical literature from the much smaller body of human evidence.
Laboratory Evidence
Numerous experimental studies have investigated molecular mechanisms and cellular responses.
Animal Evidence
A comparatively substantial preclinical literature exists across gastrointestinal, musculoskeletal and other experimental models.
Human Evidence
Human evidence remains extremely limited and has consisted mainly of small uncontrolled pilot investigations.
Established Medicine
BPC-157 has not reached this stage. No therapeutic indication has been established through regulatory approval.
What do we currently know in humans?
Human research remains far smaller and less rigorous than the extensive preclinical literature.
Published human evidence for BPC-157 remains extremely limited. Recent reviews identify fewer than 30 participants across three uncontrolled pilot studies.
One small report involved people with chronic knee pain. Another investigated interstitial cystitis. A more recent intravenous pilot investigation involved only two adults.
Although these small reports did not identify major adverse effects, their size and study design are insufficient to establish a reliable human safety profile or demonstrate clinical efficacy.
This distinction is important: encouraging animal research is a reason to conduct better clinical studies — it is not a substitute for those studies.
Where is BPC-157 in the development process?
BPC-157 remains investigational. Despite decades of preclinical work, pharmaceutical and clinical development remains substantially behind the experimental literature.
Investigational peptide
Current literature describes BPC-157 as pharmaceutically underdeveloped. Important gaps remain in standardized formulations, validated human pharmacokinetics, controlled efficacy data and comprehensive clinical safety assessment.
What don't we know yet?
Factors affecting peptide stability
Storage and stability depend on the precise formulation, physical form and analytical specification of the research material. Researchers should use the documentation applicable to the particular material under investigation.
Temperature
Temperature can affect peptide degradation and long-term chemical stability.
Light
Light exposure can contribute to degradation of susceptible research materials.
Moisture
Moisture can alter physical and chemical stability of peptide preparations.
Solution Conditions
pH, solvent, buffer composition and concentration may influence peptide stability in experimental solutions.
Investigational — not an approved medicine
BPC-157 remains an investigational peptide. Preclinical research does not establish human therapeutic efficacy, and the currently available human evidence is insufficient to establish a general safety profile or approved therapeutic use.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, dosing guidance or a recommendation for human use.
Selected scientific references
Scientific papers are listed for transparency and further academic identification. ASA Research does not use external website links within its peptide profiles.
Scientific research information only
This profile is provided for scientific and educational information. BPC-157 is an investigational compound and is not presented by ASA Research Labs as an approved medicine or treatment. Discussion of laboratory experiments, animal studies, potential applications or human research does not establish safety or efficacy. This information is not medical advice and does not provide instructions for administration, dosing or human use.